Given PB-020’s improved pharmacokinetic properties and AKT inhibitory efficacy, we tested the efficacy of combining PB-020 with the anti-PD-1 monoclonal antibody RMP1-14 on the growth of mouse MC38 CRC cells subcutaneously implanted in C57BL/6 mice in a syngeneic mouse CRC model. This evidence concerns the gene AKT1 and colorectal carcinoma.